



This article is published in its accepted form; it has not been copyedited and has not appeared in an issue of the journal. Preparation 
for inclusion in an issue of Circulation: Arrhythmia and Electrophysiology involves copyediting, typesetting, proofreading, and 
author review, which may lead to differences between this accepted version of the manuscript and the final published version. 
 
Prevalence and Phenotypic Correlations of Calmodulinopathy-Causative 
CALM1-3 Variants Detected in a Multi-Center Molecular Autopsy Cohort of 
Sudden Unexplained Death Victims 
 
Running title: Clemens et al.; Prevalence of CALM Variants in SIDS/SUDY 
 
Daniel J. Clemens, BS1; Belinda Gray, BSc(Med), MBBS, PhD2-5; Richard D. Bagnall, PhD5,6; 
David J. Tester, BS1,7; John R. Giudicessi, MD, PhD7; Joseph J. Maleszewski, MD7,8; Lia Crotti, 
MD, PhD9-11; Peter J. Schwartz, MD9; Emma Matthews, MRCP12; Christopher Semsarian, 
MBBS, PhD, MPH4-6; Elijah R. Behr, MD, PhD, MPH2,3; Michael J. Ackerman MD, PhD1,7,13 
 
1Dept of Molecular Pharmacology & Experimental Therapeutics (Windland Smith Rice Sudden Death Genomics Laboratory); 7Dept of 
Cardiovascular Medicine (Division of Heart Rhythm Services); 8Dept of Laboratory Medicine & Pathology; 13Dept of Pediatric & Adolescent 
Medicine (Division of Pediatric Cardiology), Mayo Clinic, Rochester, MN; 2Molecular & Clinical Sciences Rsrch Inst, St George's Univ of 
London; 3Cardiology Clinical Academic Group, St George's Univ Hospitals' National Health Service (NHS) Foundation Trust, London, UK; 
4Sydney Medical School Faculty of Medicine & Health, 6Agnes Ginges Centre for Molecular Cardiology at Centenary Inst, The Univ of Sydney; 
5Dept of Cardiology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; 9Istituto Auxologico Italiano, IRCCS, Center for Cardiac 
Arrhythmias of Genetic Origin & Laboratory of Cardiovascular Genetics; 10Istituto Auxologico Italiano, IRCCS Dept of Cardiovascular, Neural 
& Metabolic Sciences, San Luca Hospital; 11Dept of Medicine & Surgery Univ of Milano-Bicocca, Milan, Italy; 12Queen Square Centre for 





Michael J. Ackerman, MD, PhD 
Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory 
Guggenheim 501, Mayo Clinic 
200 First Street SW, Rochester, MN 55905 





Journal Subject Terms: Arrhythmias; Genetics; Pediatrics; Sudden Cardiac Death 
 
 











This article is published in its accepted form; it has not been copyedited and has not appeared in an issue of the journal. Preparation 
for inclusion in an issue of Circulation: Arrhythmia and Electrophysiology involves copyediting, typesetting, proofreading, and 
author review, which may lead to differences between this accepted version of the manuscript and the final published version. 
Nonstandard Abbreviations and Acronyms 
sudden unexplained death (SUD) 
sudden infant death (SID) 




Sudden unexplained death (SUD) is a profoundly tragic event for families and their 
communities. These cases can be categorized into two main groups including sudden infant death 
syndrome (SIDS, < 1year of age), and SUD in the young (SUDY, 1-35 years). In the US alone, 
SIDS accounts for approximately 3000 sudden deaths each year, while SUDY occurs in up to 
5000 individuals annually.1 Approximately 10% of SIDS and 25% of SUDY may be caused by 
pathogenic variants in cardiac channelopathy-susceptibility genes.2   
Three different calmodulin genes, CALM1 (chr14q21), CALM2 (chr2p21), and CALM3 
(chr19q13), each of which has a distinct genomic locus and unique nucleotide sequence, all 
encode for an identical 149 amino acid calmodulin protein (CaM).3 Since 2012, pathogenic 
variants in CALM1-3-encoded CaM, approximately 90% of which are de novo, have been 
implicated as the underlying cause of multiple arrhythmic phenotypes including long QT 
syndrome (CaM-LQTS), catecholaminergic polymorphic ventricular tachycardia (CaM-CPVT), 
and idiopathic ventricular fibrillation (CaM-IVF), collectively termed the calmodulinopathies.4  
Data from the recently published International Calmodulinopathy Registry found that 
68% of 74 calmodulinopathic patients have suffered at least one major arrhythmic event at an 
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despite its malignant and potentially lethal phenotype, the prevalence of calmodulinopathic 
variants in cases of SIDS and SUDY remains unknown.  
Here, we determined the spectrum and prevalence of CALM1-3 pathogenic variants in a 
large multi-center cohort of 599 SIDS and 258 SUDY cases contributed from three international 
medical centers in the United States, United Kingdom, and Australia. In order to prevent the re-
identification of individuals included in this study, individual patient data will not be made 
available to other researchers. This study complies with the Declaration of Helsinki; locally 
appointed ethics committees including Mayo Clinic’s Institutional Review Board have approved 
the research protocol.  
Of the SIDS cases, 362 (60%) were male and 237 (40%) were female. The median age at 
death was 2 months (interquartile range (IQR) 1-4 months), and 349 (58%) of these cases were 
white. In the SUDY cohort, 176 (68%) cases were male and 82 (32%) were female. The median 
age at death was 21 years (IQR 16-29 years) with 88% dying between the ages of 1-35 years and 
196 (76%) were white.  
Postmortem genomic DNA, derived from each decedent, underwent either whole exome 
or targeted gene panel sequencing followed by a gene-specific analysis of CALM1, CALM2, and 
CALM3, using Ingenuity Variant Analysis software. Only rare (minor allele frequency ≤ 0.005% 
in gnomAD) nonsynonymous variants with a call quality score of ≥ 20 and a read depth of ≥ 10 
were considered. Identified variants were classified according to the American College of 
Medical Genetics (ACMG) guidelines.  
Overall, we identified a pathogenic CALM1-3 variant in 3 out of 857 SUD cases 
(0.035%). Interestingly, none of these variants were present in our SIDS cohort (0/599, 0%), but 
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pathogenic CALM 1-3 variants was significantly higher in SUDY cases dying between the ages 
of 1 and 10 years (3/32, 9.4%) compared to those older than 10 years at age of death (0/226, 0%; 
p=0.002; Figure 1B). In comparison, approximately 7% of our SIDS cohort and 26% of our 
SUDY cohort hosted a rare nonsynonymous variant in one of the four major channelopathy 
genes (KCNQ1, KCNH2, SCN5A, or RYR2).   
A CaM-p.Asn54Ile variant (CALM1, c.161A>T) was identified in a 9-year-old female 
who died suddenly following extreme emotion. This variant is located in the inter-EF-hand I-II 
linker domain and is known to cause CaM-CPVT (Figure 1C).4 The second variant, CaM-
p.Phe90Leu (CALM2, c.268T>C), which resides in the inter-EF-hand II-III linker domain was 
found in a 5-year-old male who experienced sudden death during physical exertion. While this 
variant has not been identified before in CALM2, CALM1-p.Phe90Leu has been associated 
previously with CaM-IVF previously (Figure 1C).4 The CaM-p.Asn98Ser variant (CALM2, 
c.293A>G) was identified in a 2-year-old male who died suddenly while engaging in toddler 
play. This variant is located in the EF-hand III domain and has been associated with both LQTS 
and CPVT in CALM1- and CALM2-encoded calmodulin (Figure 1C).4 However, patients with 
the p.Asn98Ser variant typically do not express an overt LQTS phenotype.5   
Although CaM-LQTS patients exhibit a more malignant phenotype and have a higher rate 
of SCD than other calmodulinopathy phenotypes, it is not surprising that the CALM variants 
identified in our SUDY cases have been associated with CaM-CPVT or CaM-IVF and not CaM-
LQTS. Typically, CaM-LQTS manifests with severe and readily detectable clinical features 
(QTc > 550 ms, bradycardia, 2:1 AV block, T-wave alternans) often occurring during infancy 
and is therefore likely detected prior to the occurrence of sudden death. Thus, the absence of 
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expressivity. In contrast, CaM-CPVT and CaM–IVF patients do not display the same readily 
detectable clinical feature and may elude detection until a sentinel event of SCD after the first 
year of life. Additionally, channelopathies are responsible for a greater percentage of SUDY than 
SIDS and therefore larger number of cases may be needed to identify CALM-related SIDS cases.  
While pathogenic variants in CALM1-3 do not contribute meaningfully to SIDS, about 
1% of SUDY overall stems from pathogenic CALM variants. Additionally, CALM variants may 
account for up to 10% of the SUD cases occurring during childhood. Therefore, the CALM1, 
CALM2, and CALM3 genes should be included in postmorterm genetic testing (aka, the 
molecular autopsy), especially in children who have died between the ages of 1-10 years.     
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Figure 1. Yield and Location of CALM Variants Identified in SIDS and SUDY. A. A table 
showing the yield of CALM variants in the SIDS and SUDY cohorts and in SUDY cases between 
the ages of 1-10 years and those > 10 years of age. B. A schematic of the CaM protein showing 
the N- and C-domains, each with two EF hands (EF-I through EF-IV) with calcium (red) bound. 
Blue circles represent WT residues, and white circles represent variants identified in our SUDY 
cohort. Combined Annotation Dependent Depletion (CADD) score > 20 is considered an in 
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